Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Seattle Genetics, Inc.    SGEN

SEATTLE GENETICS, INC.

(SGEN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/19/2019 03/20/2019 03/21/2019 03/22/2019 03/25/2019 Date
72.86(c) 72.77(c) 75.31(c) 73.99(c) 73.87(c) Last
412 928 391 859 661 766 772 406 765 760 Volume
-0.82% -0.12% +3.49% -1.75% -0.16% Change
More quotes
Financials (USD)
Sales 2019 817 M
EBIT 2019 -166 M
Net income 2019 -161 M
Finance 2019 162 M
Yield 2019 -
Sales 2020 1 060 M
EBIT 2020 0,61 M
Net income 2020 0,33 M
Finance 2020 229 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020 2 402,27
EV / Sales2019 14,3x
EV / Sales2020 11,0x
Capitalization 11 880 M
More Financials
Company
Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed... 
More about the company
Surperformance© ratings of Seattle Genetics, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on SEATTLE GENETICS, INC.
03/05SEATTLE GENETICS : to Present at Cowen and Company 39th Annual Health Care Confe..
BU
02/11SEATTLE GENETICS : Achieves $30 Million Milestone Payment for European Commissio..
BU
02/07SEATTLE GENETICS : WA Management's Discussion and Analysis of Financial Conditio..
AQ
02/07SEATTLE GENETICS : 4Q Earnings Snapshot
AQ
02/07SEATTLE GENETICS INC /WA : Results of Operations and Financial Condition (form 8..
AQ
02/07SEATTLE GENETICS : Reports Fourth Quarter and Full Year 2018 Financial Results
BU
02/06SEATTLE GENETICS : to Present at Guggenheim Healthcare Talks Idea Forum | Oncolo..
BU
01/22SEATTLE GENETICS : to Host Conference Call and Webcast Discussion of Fourth Quar..
BU
01/11SEATTLE GENETICS : UW team builds protein that avoids IL-2 toxicities, forms Neo..
AQ
01/10SEATTLE GENETICS : Announces Publication of North American Subgroup Data from EC..
AQ
More news
Analyst Recommendations on SEATTLE GENETICS, INC.
More recommendations
Sector news : Biotechnology & Medical Research - NEC
03/11Regeneron Says FDA Approves Dupixent for Atopic Dermatitis in Adolescents
DJ
03/08Regeneron, Sanofi Get FDA Priority Review for Dupixent
DJ
03/07SHANGHAI RAAS BLOOD PRODUCTS : Spain's Grifols, China's Shanghai RAAS form strat..
RE
03/06GILEAD SCIENCES : Says Once-Daily HIV Regimen Shows Promise in Treating Teens an..
DJ
03/05FDA Approves Controversial Drug for Depression -- Update
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart SEATTLE GENETICS, INC.
Duration : Period :
Seattle Genetics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEATTLE GENETICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 79,4 $
Spread / Average Target 7,3%
EPS Revisions
Managers
NameTitle
Clay B. Siegall Chairman, President & Chief Executive Officer
Todd E. Simpson CFO & Principal Accounting Officer
Vaughn B. Himes Chief Technical Officer
Robert J. Lechleider Senior Vice President-Clinical Development
Roger D. Dansey Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
SEATTLE GENETICS, INC.30.59%11 880
IQVIA HOLDINGS INC21.93%28 018
CELLTRION, INC.--.--%22 489
LONZA GROUP13.27%21 615
INCYTE CORPORATION34.20%18 267
EXACT SCIENCES CORPORATION41.05%11 193